Daan P. Hurkmans

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal: Journal for immunotherapy of cancer

Published: June 15, 2026

Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial.

Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial.

Journal: Diagnostic and prognostic research

Published: February 13, 2026

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: July 31, 2025

Re: Policy Versus Practice: Facilitators and Barriers of Chronic Care Integration in Dutch General Practice - a Survey Study.

Re: Policy Versus Practice: Facilitators and Barriers of Chronic Care Integration in Dutch General Practice - a Survey Study.

Journal: International journal of integrated care

Published: June 25, 2025

Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.

Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 28, 2022

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2022

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Journal: Cellular and molecular life sciences : CMLS

Published: December 07, 2021

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.

Journal: Journal for immunotherapy of cancer

Published: April 27, 2021

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy.

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy.

Journal: Cancers

Published: January 27, 2021

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.

Journal: Journal for immunotherapy of cancer

Published: November 15, 2020

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.

Journal: Journal for immunotherapy of cancer

Published: October 02, 2020

The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.

The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.

Journal: Journal of cachexia, sarcopenia and muscle

Published: September 18, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026